Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.

@article{Seghers2012SuccessfulRI,
  title={Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.},
  author={Am{\'e}lie Cl{\'e}mentine Seghers and Sofie Wilgenhof and C{\'e}l{\`e}ste Lebb{\'e} and Bart Neyns},
  journal={Melanoma research},
  year={2012},
  volume={22 6},
  pages={466-72}
}
The v-raf murine sarcoma viral oncogene homolog B1 (BRAF) gene is mutated at position 600 in about 50% of melanoma. Mutant BRAF activates the downstream effectors of the RAS-RAF-MEK-MAPK pathways and is a driver oncogene in these melanoma cells. Selective BRAF-V600 inhibitors (vemurafenib, dabrafenib) have high antitumor activity against BRAF-V600-mutant melanoma with objective tumor response rates. Resistance, however, develops within less than a year in the majority of patients. Several… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
38 Citations
27 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

A phase I clinical trial on the combined intravenous (IV) and intradermal (ID) administration of autologous TriMix-DC cellular therapy in patients with pretreated melanoma (TriMixIDIV)

  • B Neyns, S Wilgenhof, AMT Van Nuffel, D Benteyn, C Heirman, I Van Riet
  • ASCO Meeting Abstracts
  • 2011

Similar Papers

Loading similar papers…